StockIQ.techMerck KGaA (MRK.DE) Stock Analysis
Free AI-powered analysis and research for Merck KGaA stock
Sector: Healthcare
MRK.DE snapshot
Data as of 4 Nov 2026 close. Updated daily.
Merck KGaA scores 99/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 97% of its 52-week range, up 33.5% over the past year. Latest reported figures show a profit margin of 11.2%, return on equity of 8.1% and revenue growth of +3.4%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Good Profit Margin (11.2%): +5
- Strong Long-term Uptrend: +8
- Strong Momentum (+33.5% over 1 year): +8
- High Volume (1.9x): +3
- Near 52-Week High (97%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full MRK.DE report
Merck KGaA (MRK.DE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MRK.DE Now →📰 Latest Update
Biobanks - Global Strategic Business Report: Capitalize on a US$51.7 Billion Revenue Surge by 2030 as Thermo Fisher Scientific, Merck KGaA, BioLifeSolutions, and Tecan Reshape the Market
Tue, November 3, 2026 at 3:11 PM UTC 2 min read
The global biobanks market, valued at US$91.6 billion in 2024, is projected to reach US$143.3 billion by 2030, growing at a CAGR of 7.7%. The report highlights the increasing importance of biobanks in genomics and precision medicine, driven by rising chronic disease prevalence and investment in personalized medicine. It also discusses technological advancements and collaborations among various sectors that are enhancing operational efficiency and expanding biobank capabilities.